NCT04749433View on ClinicalTrials.gov

Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS

PHASE1TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2023

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

[11C]CPPC Injection

A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.

Trial Locations (1)

21287

Johns Hopkins Outpatient Center, Baltimore

Sponsors

Collaborators (1)

Precision Molecular

All Listed Sponsors

collaborator

Precision Molecular

UNKNOWN

lead

Johns Hopkins University

OTHER